Mon, Dec 23, 2024 13:05 CET Report this content Medivir will present final safety and efficacy data from its phase Ib/IIa liver cancer study of fostrox in combination with Lenvima at the EASL Liver Cancer Summit in Paris, early next year. The data will be shared by Dr. …
BioStock: Medivir to highlight promising clinical data at EASL
Medivir will present final safety and efficacy data from its phase Ib/IIa liver cancer study of fostrox in combination with Lenvima at the EASL Liver Cancer Summit in Paris, early next year. The data will be shared by Dr. Jeff Evans from the Beatson West of Scotland Cancer Center in Glasgow, UK.
Read the article at biostock.se:
https://www.biostock.se/en/2024/12/medivir-to-highlight-promising-clinical-data-at-easl/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
